Arsenic trioxide in recurrent urothelial cancer: A Cancer and Leukemia Group B phase II trial (CALGB 99903) Journal Article
| Authors: | Bajorin, D. F.; Halabi, S.; Small, E. |
| Article Title: | Arsenic trioxide in recurrent urothelial cancer: A Cancer and Leukemia Group B phase II trial (CALGB 99903) |
| Abstract: | Background: Arsenic trioxide is highly active in patients with acute promyelocytic leukemia. There are also preclinical data to suggest that this drug might be active in nonhematopoietic malignancies, and transitional cell carcinoma cell lines are particularly sensitive to this agent. Patients and Methods: Twelve evaluable patients with metastatic urothelial cancer were treated with arsenic trioxide in a phase II trial conducted by the Cancer and Leukemia Group B. Eligible patients were required to have measurable urothelial cancer and a maximum of 1 previous chemotherapy regimen. Arsenic trioxide was given at a dose of 0.3 mg/kg daily for 5 days every 28 days. Results: No major responses were observed; 4 patients achieved stable disease. The median survival was 6.5 months (95% CI, 3.9-13.4 months). The most commonly observed toxicities included fatigue and malaise, anemia, nausea, emesis, and constipation. Conclusion: Arsenic trioxide at this dose and schedule does not have significant activity in previously treated urothelial cancer and has substantial toxicity in this patient population. |
| Keywords: | adult; cancer survival; clinical article; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; survival rate; overall survival; clinical trial; constipation; drug tolerability; fatigue; neutropenia; cisplatin; cancer growth; drug dose reduction; drug withdrawal; hypophosphatemia; side effect; antineoplastic agents; gemcitabine; paclitaxel; recurrent cancer; anorexia; carboplatin; edema; metastasis; drug eruption; infection; multiple cycle treatment; nephrotoxicity; pain; phase 2 clinical trial; sensory neuropathy; anemia; bone marrow suppression; esophagitis; nausea; dehydration; weight reduction; recurrence; hypercalcemia; urogenital tract cancer; urinary bladder neoplasms; dyspnea; febrile neutropenia; hyperglycemia; lung embolism; metastatic transitional cell carcinoma; urothelial tract cancer; alanine aminotransferase; alkaline phosphatase; arsenic trioxide; aspartate aminotransferase; bilirubin; acute kidney failure; allergic rhinitis; cause of death; chemotherapy induced emesis; confusion; creatinine urine level; drug fatality; drug induced headache; dysphagia; gastrointestinal toxicity; heart palpitation; hyperkalemia; hypermagnesemia; hypoalbuminemia; hypokalemia; hyponatremia; hypotension; insomnia; liver failure; maculopapular rash; malaise; odynophagia; prothrombin time; skin exfoliation; survival time; arsenicals; leukemia, promyelocytic, acute; oxides; urologic neoplasms; urothelium |
| Journal Title: | Clinical Genitourinary Cancer |
| Volume: | 7 |
| Issue: | 3 |
| ISSN: | 1558-7673 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2009-10-01 |
| Start Page: | E66 |
| End Page: | E70 |
| Language: | English |
| DOI: | 10.3816/CGC.2009.n.026 |
| PUBMED: | 19815484 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "Source: Scopus" |
